[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"long-qt-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:long-qt-syndrome":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,68,106,131,182,204,235,259],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100642535","ai-powered-ecg-analysis-for-deadly-arrhythmias-and-ici-myocarditis-100642535",false,"NCT07644715","AI-powered ECG Analysis for Deadly Arrhythmias and ICI Myocarditis","Efficient Deep Learning Approaches for the Rapid and Interpretable Detection of Deadly Arrhythmias in ECG Data","ELDORA","Inclusion Criteria:\n\n* subjects included in participating existing or ongoing ECG cohorts made available to ECGInsight\n* availability of ECG data (digital waveform or scanned\u002Fpaper ECG suitable for digitization) and relevant clinical\u002Fdemographic metadata\n* data use permitted by applicable ethical, regulatory, contractual and GDPR requirements.\n\nExclusion Criteria:\n\n* datasets or individual records for which required approvals, data-sharing agreements, de-identification\u002Fanonymization, or minimum ECG\u002Fmetadata quality requirements are not met. No interventional study treatment is assigned.",true,"ALL",{"count":20,"type":21},127000,"ESTIMATED","OBSERVATIONAL","ELDORA is a non-interventional observational data-science study aiming to develop and validate clinical-grade artificial intelligence tools applied to electrocardiogram (ECG) data. The project will standardize heterogeneous ECGs, create the ECGInsight harmonized database, and train interpretable models for life-threatening arrhythmia risk prediction, especially Torsades-de-Pointes\u002Flong QT syndrome and immune checkpoint inhibitor (ICI)-induced myocarditis. The project uses existing and ongoing national and international ECG cohorts with de-identified clinical metadata; AI outputs are intended for research\u002Fmodel development and are not used to drive patient care during the study.",[25,26,27],"Arrhythmia","Long QT Syndrome","Immune Checkpoint Inhibitor-Related Myocarditis",[29,30,31,32],"ECG","AI","Immune Checkpoint Inhibitors-Related Myocarditis","long QT","RECRUITING","2026-06-08",{"date":36,"type":37},"2026-06-12","ACTUAL",{"date":39,"type":37},"2026-01-01",{"date":41,"type":21},"2029-12-31",{"name":43,"class":44},"Groupe Hospitalier Pitie-Salpetriere","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":45},"100584288","wearable-devices-for-patient-monitoring-in-long-qt-syndrome-100584288","NCT06887387","Wearable Devices for Patient Monitoring in Long QT Syndrome","Application of Wearable Devices for Remote QT Interval Monitoring and Symptom Investigation for Patients With Long QT Syndrome","Inclusion Criteria:\n\n* Clinical diagnosis of Long QT Syndrome\n* Aged 18 years or over\n* Phone with iOS version 15 or Android OS 9.0 or higher\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Unwilling or unable to give consent\n* Ventricular pacing at recruitment\n* Bundle branch block or pre-excitation at baseline","18 Years",{"count":55,"type":21},80,"3 Months","The main research question of this study is whether wearable devices have utility in monitoring patients with Long QT syndrome.",[26],"2026-05-18",{"date":61,"type":37},"2026-05-19",{"date":63,"type":37},"2025-04-01",{"date":65,"type":21},"2026-09-04",{"name":67,"class":44},"Queen Mary University of London",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":75,"targetDuration":77,"studyType":22,"phases":4,"briefSummary":78,"conditions":79,"keywords":93,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100558055","national-network-for-cardiovascular-genomics-advancing-cardiovascular-healthcare-for-hereditary-diseases-in-brazils-unified-health-system-through-a-multicenter-registry-100558055","NCT06546137","National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry","RENOMICA-Hcor","Inclusion Criteria:\n\n* Clinical diagnosis of a hereditary cardiovascular disease according to current clinical guidelines\n* Agree to receive genetic counseling\n* Sign informed consent form\n* Provide the information required in the case report form\n\nExclusion Criteria:\n\n* Signature absent from informed consent form\n* Inadequate buccal swab (sample may be collected twice)",{"count":76,"type":21},1211,"6 Months","The goal of this observational study is to develop a registry of Brazilian patients with hereditary cardiovascular diseases, combining clinical and genomic data. The main questions it aims to answer are:\n\nWhich genes are most commonly affected? What is the frequency of these genetic alterations in our population? Participants will be interviewed in routine medical care visits and their DNA will be sequenced.",[80,81,82,83,84,85,86,87,88,26,89,90,91,92],"Cardiomyopathy, Hypertrophic","Cardiomyopathy, Dilated","Cardiomyopathy Restrictive","Arrhythmogenic Right Ventricular Dysplasia","Non-Compaction Cardiomyopathy","Familial Hypercholesterolemia","Marfan Syndrome","Ehlers-Danlos Syndrome, Vascular Type","Loeys-Dietz Syndrome","Short Qt Syndrome","Brugada Syndrome","Catecholaminergic Polymorphic Ventricular Tachycardia","Sudden Cardiac Death",[94,95],"hereditary cardiovascular diseases","whole genome sequencing","2026-05-04",{"date":98,"type":37},"2026-05-08",{"date":100,"type":37},"2025-04-30",{"date":102,"type":21},"2026-08-31",{"name":104,"class":44},"Hospital do Coracao",27,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":115,"phases":116,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":45},"100466041","comparing-direct-vs-indirect-methods-for-cascade-screening-100466041","NCT05348564","Comparing Direct vs Indirect Methods for Cascade Screening","Comparing Direct and Indirect Methods for Cascade Screening in Familial Hypercholesterolemia (FH) and Long QT Syndrome (LQTS)","Proband Inclusion Criteria:\n\n* KCNQ1 Thr224Met or APOB R3527Q carrier\n* 18 years or older\n\nProband Exclusion Criteria:\n\n* None\n\nFamily Inclusion Criteria:\n\n* 1st degree relative of a KCNQ1 Thr224Met or APOB Arg3527Gln carrier\n\nFamily Exclusion Criteria:\n\n* None",{"count":114,"type":21},200,"INTERVENTIONAL",[117],"NA","An important aspect of successful genomic medicine implementation is developing effective approaches for screening at-risk family members after probands are identified, also known as cascade screening. Most cascade screening studies conducted to date have been conducted outside the US, and very few studies have used a rigorous approach involving a comparator group or randomized controlled design. A major question in the field is how to most effectively implement cascade screening, given commonly cited communication barriers, while respecting privacy among probands and family members. This study will conduct a randomized controlled trial to assess direct contact of relatives by study team members vs indirect, or proband-initiated, contact. We will assess efficacy of the cascade screening intervention, patient-centered outcomes regarding mental, physical, and psychosocial outcomes in probands and family members, and implementation evaluation outcomes.\n\nIndividuals who are known to carry the KCNQ1 Met224Thr or APOB Arg3527Gln variant will be eligible to participate. After providing consent and being deemed eligible, individuals will be randomized in a 1:1 manner into the direct or indirect contact of family members arm of the study. The randomization will be stratified by variant to ensure equal representation of each variant in the study arms. Individuals in the indirect arm will be instructed to contact their first-degree family members about the opportunity to be screened. They will be provided with a disease-specific pamphlet and a family letter explaining the cascade screening. In the direct arm, probands will be advised that the study staff will be contacting their family members. They will be instructed to also contact their family members prior to the study team contacting them. Approximately two weeks after this meeting with the proband, the study staff will mail letters to eligible first-degree family members of the probands. If we do not hear back from individual family members, we will follow-up with another letter, telephone call, or home visit. The information contained in the letters will be the same information for both the direct and indirect arms of the study. All interested family members will receive pre-test counseling and free, in-home, saliva-based genetic testing, and post-test counseling.",[26,85,120,121],"Ethics","Genetic Testing","2026-04-10",{"date":124,"type":37},"2026-04-14",{"date":126,"type":37},"2023-05-15",{"date":128,"type":21},"2027-10",{"name":130,"class":44},"University of Maryland, Baltimore",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":138,"minAge":53,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":141,"conditions":142,"keywords":160,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":181},"100345304","fetal-electrophysiologic-abnormalities-in-high-risk-pregnancies-associated-with-fetal-demise-100345304","NCT03775954","Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise","Fetal Electrophysiologic Abnormalities in High-risk Pregnancies Associated With Fetal Demise","Inclusion Criteria:\n\n* Current pregnancy complicated by one of the five diagnostic categories\n\n  * prior unexplained Stillbirth at\u002Fafter 20 weeks gestation\n  * fetal major congenital heart defect\n  * fetal hydrops\n  * fetal gastroschisis\n  * monochorionic twin pregnancy\n* Subject must be 18 years of age or older\n* Subject must be English speaking and must be able to read and sign the consent form in English\n* Subject must be able to recline comfortably for 1-3 hours\n* Subject must be willing to complete all three procedures (fMCG, fMCG, nECG) as per protocol, unless medically unable\n* Subject must be willing to allow us to review her and her infants prenatal, deliver, and post-natal records to verify diagnosis, and clinical findings.\n\nExclusion Criteria:\n\n* Severe claustrophobia not reduced by taking breaks, or by having the light on, or by having someone in the room with them.\n* Active labor\n* Acute illness\n* Unable to recline comfortably with a pillow for more than 1-3 hours (assuming some breaks are provided)\n* Weight over 450 lbs\n* An electric stimulation device (TENS unit, pacemaker, or nerve stimulator) that could produce electric or magnetic noise.\n\n  * Note that the Tristan 624 Magnetometer does not pose a risk to the subject's device, (since fMCG does not produce any energy or magnetism), but stimulators themselves can cause interference for our recordings. Some devices may still qualify, and discussion with study nurse may be useful if subject has a pacemaker or similar device.\n\nThe subject will have a single 2-3 hour fetal magnetocardiogram at approximately 20 and 27 weeks GA, and again, if medical condition allows, between 30 and 37 weeks GA, then her infant will have an ECG between 0 and 4 weeks of age. Subjects will be paid a nominal fee for their participation each time, as well as transportation reimbursement if \\>25 miles. For subjects traveling a long distance, the ECG may be performed locally or at home.","FEMALE",{"count":140,"type":21},30,"Each year world-wide, 2.5 million fetuses die unexpectedly in the last half of pregnancy, 25,000 in the United States, making fetal demise ten-times more common than Sudden Infant Death Syndrome. This study will apply a novel type of non-invasive monitoring, called fetal magnetocardiography (fMCG) used thus far to successfully evaluate fetal arrhythmias, in order to discover potential hidden electrophysiologic abnormalities that could lead to fetal demise in five high-risk pregnancy conditions associated with fetal demise.",[143,144,145,146,147,148,149,150,26,151,152,153,154,155,156,157,158,90,159],"High Risk Pregnancy","Congenital Heart Disease","Fetal Hydrops","Twin Monochorionic Monoamniotic Placenta","Gastroschisis","Fetal Demise","Stillbirth","Fetal Arrhythmia","Intrauterine Fetal Death","Sudden Infant Death","Pregnancy Loss","Twin Twin Transfusion Syndrome","Birth Defect","Fetal Cardiac Anomaly","Fetal Cardiac Disorder","Fetal Death","Fetal Tachycardia",[161,149,162,163,164,143,165,166,167,168,169,170,171],"Fetal Magnetocardiography","Intrauterine Fetal Demise","Fetal Heart Rate Variability","Fetal Arrhythmias","Pregnancy","Fetal Anomaly","Fetal Echocardiography","Non-Stress Testing","New Technology","Birth Defects","Fetal Research","2026-03-02",{"date":174,"type":37},"2026-03-04",{"date":176,"type":37},"2018-07-01",{"date":178,"type":21},"2028-11-30",{"name":180,"class":44},"Medical College of Wisconsin",2,{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":115,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":45},"100388350","continuous-versus-intermittent-cardiac-electrical-monitoring-100388350","NCT04336644","Continuous Versus Intermittent cARdiac Electrical moNitorinG","CARING","Inclusion Criteria:\n\n* Diagnosis of acute promyelocytic leukemia (APL) and being initiated on standard of care arsenic trioxide OR Diagnosis of solid tumor and being initiated on standard of care capecitabine (alone or as part of combination treatment) OR Diagnosis of solid tumor and being initiated on standard of care ribociclib (alone or as part of combination treatment)\n* At least 18 years of age.\n* No allergy to adhesive patches.\n* Able to understand and willing to sign an IRB-approved written informed consent document.\n\nExclusion Criteria:\n\n* Younger than 18 years of age\n* Allergy to adhesive patches",{"count":190,"type":21},60,[117],"The purpose of this study is to validate the continuous patch monitoring system to evaluate cardiac arrhythmias in patients receiving drugs that can cause cardiac complications and compare the continuous patch system with standard electrocardiograms (ECGs).",[194,26],"Torsades de Pointe Caused by Drug","2025-12-28",{"date":197,"type":37},"2025-12-30",{"date":199,"type":37},"2023-11-21",{"date":201,"type":21},"2026-12-31",{"name":203,"class":44},"Washington University School of Medicine",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":17,"sex":18,"minAge":212,"maxAge":213,"enrollmentInfo":214,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":216,"conditions":217,"keywords":220,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":181},"100566907","evaluation-of-exercise-testing-and-physical-activity-in-children-and-adolescents-living-with-inherited-arrhythmias-100566907","NCT06661278","Evaluation of Exercise Testing and Physical Activity in Children and Adolescents Living With Inherited Arrhythmias","Evaluation of Free-living Physical Activity and the Assessment Tools Used to Support Pharmacological Therapy Titration and Exercise Prescription in Children and Adolescents Diagnosed With Inherited Arrhythmias","ACTIVELY","Inclusion Criteria:\n\nAffected cohort\n\n* Male and female children\n* Aged 6-16 years\n* Diagnosed with long QT syndrome or catecholaminergic polymorphic ventricular tachycardia\n* Treated with beta-blocker and\u002For sodium channel blockade\n* Able to complete a treadmill ETT\n\nHealthy cohort\n\n* Male and female children\n* Aged 6-16 years\n* Siblings of affected children (gene negative)\n* Undergoing IAS screening\n* Able to complete a treadmill ETT\n\nExclusion Criteria:\n\n* Children aged less than 6 years\n* Adults, 17 years of age and above\n* Unable to run on an exercise treadmill due to physical limitations.\n* Individuals unable to speak or understand English, due to no translation service available.\n* Pregnancy","6 Years","16 Years",{"count":215,"type":21},110,"The goal of this observational study is to evaluate exercise testing and daily physical activity in children and adolescents who are diagnosed with an inherited arrhythmia.\n\nThe main question it aims to answer is: Does maximum heart rate during controlled exercise tolerance testing accurately reflect maximum heart rate and peak exercise levels during free living daily physical activity in children and adolescents diagnosed with an inherited arrhythmia?\n\nParticipants will:\n\n* Complete routine exercise tolerance testing\n* Record daily physical activity and exercise over two weeks, while wearing an activity and heart rate monitor and digit diary.\n* Complete a physical activity questionnaire at the end of two weeks.",[26,218,219],"Catecholaminergic Polymorphic Ventricular Tachycardia Type 1","Catecholaminergic Polymorphic Ventricular Tachycardia Type 2",[221,222,223,224,225],"Children","Adolescents","Exercise","Physical activity","Exercise tolerance testing","2025-05-30",{"date":228,"type":37},"2025-05-31",{"date":230,"type":37},"2025-03-18",{"date":232,"type":21},"2025-12-31",{"name":234,"class":44},"Royal Brompton & Harefield NHS Foundation Trust",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":245,"conditions":246,"keywords":247,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":181},"100522803","building-of-a-diagnosticprognostic-database-for-human-erg-variant-effects-100522803","NCT06087367","Building of a Diagnostic\u002FPrognostic Database for Human ERG Variant Effects","Building of a Diagnostic\u002FPrognostic Database by High-throughput Multiplexed Assays for Human ERG Variant Effects","CarDiag","Inclusion Criteria:\n\n* Patients carrier of a mutation in KCNH2 gene\n\nExclusion Criteria:\n\n* Patients who refuse to take part to research",{"count":244,"type":21},600,"Cardiac channelopathies induce severe heart rhythm or conduction disorders. Mutations of the KCNH2 gene, that encodes the human (h) ERG channel, is responsible for 30-40% of all cases of long QT syndrome (inherited LQT2). Besides, hERG is frequently responsible for off-target effects of several pharmacological agents (acquired LQT2). With the advent of Next Generation Sequencing, hundreds of new KCNH2 variants are accumulating in regional databases including those developed by french centers of references. Worldwide, we estimate there are more than 1000 variants for hERG channel. Unfortunately, many of these new variants appear to be of unknown functional significance in spite of available clinical and genetic information. Little is known on whether they affect the channel biophysical properties, its expression at the cell surface and\u002For its structure. Yet, this information is crucial to determine the real degree of pathogenicity of these variants, and therefore to make the proper diagnosis on inherited LQT2, counsel the patient for his treatment and improve the management of the patient's life. Our ambition is therefore to tackle this issue of variant significance by (i) launching a large-scale multi-functional evaluation of hERG variants, (ii) introducing for the first time a formatted large-scale pathogenicity annotation score for all variants that have been functionally evaluated by this multi-parametric approach, and (iii) regrouping all the relevant information collected in every French Regional centers of reference into a single National database hosted by an infrastructure that possesses enough flexibility for continuous data implementation and cross-referencing. The database will integrate the latest International guidelines for functional pathogenicity annotation. This project will also include the pharmacological characterization of several drugs susceptible to produce acquired LQT2 with variable severities. We aim to understand whether there are structural regions within hERG channel in which the introduction of a variant is more prone to increase the risk of acquired LQT2 or if, on the contrary, a set of variants may relatively protect some patients against LQT2-inducing drugs.",[26],[248,249],"Long QT syndrome","KCNH2 gene variants","2025-05-22",{"date":252,"type":37},"2025-05-23",{"date":254,"type":37},"2021-09-20",{"date":256,"type":21},"2026-03-24",{"name":258,"class":44},"Nantes University Hospital",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":17,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":267,"targetDuration":269,"studyType":22,"phases":4,"briefSummary":270,"conditions":271,"keywords":280,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":45},"100479320","clinical-cohort-study---trust-100479320","NCT05521451","Clinical Cohort Study - TRUST","Longterm Outcome and Predictors for Recurrence After Medical and Interventional Treatment of Arrhythmias At the University Heart Center Hamburg","TRUST","Inclusion Criteria:\n\n* Cardiac arrhythmia, including congenital cardiac arrhythmia diagnosed at baseline or high risk for cardiac arrhythmia\n* Age ≥ 18 years\n* Written informed consent\n* Ability to provide written informed consent in accordance with Good Clinical Practice and local legislation\n\nExclusion Criteria:\n\n* Insufficient knowledge of the German language to understand study documents and interview without translation\n* Physical or psychological incapability to cooperate in the investigation",{"count":268,"type":21},5000,"10 Years","The \"Long-term Outcome and Predictors for Recurrence after Medical and Interventional Treatment of Arrhythmias at the University Heart Center Hamburg\" (TRUST) study is an investor-initiated, single-center, prospective clinical cohort study including patients treated with cardiac arrhythmias or at high risk for cardiac arrhythmias. The design enables prospective, low-threshold, near complete inclusion of patients with arrhythmias treated at the UHZ. Collection of routine follow-up data, detailed procedural information and systematic biobanking will enable precise and robust phenotyping.",[272,273,274,275,276,83,26,90,277,91,278,279],"Arrhythmias, Cardiac","Atrial Fibrillation","Atrial Flutter","Ventricular Tachycardia","Atrial Tachycardia","Supraventricular Tachycardia","Torsades De Pointes","Atrial Cardiomyopathy",[281,282,283,284,285,286,279],"Catheter Ablation","Biomarkers","Cardiac Arrhythmia","eHealth","Digital Cardiology","Echocardiography","2025-03-25",{"date":289,"type":37},"2025-03-30",{"date":291,"type":37},"2021-03-17",{"date":293,"type":21},"2031-12-31",{"name":295,"class":44},"Universitätsklinikum Hamburg-Eppendorf"]